List of Xartemis Xr drug patents

Xartemis Xr is owned by Mallinckrodt Inc.

Xartemis Xr contains Acetaminophen; Oxycodone Hydrochloride.

Xartemis Xr has a total of 12 drug patents out of which 0 drug patents have expired.

Xartemis Xr was authorised for market use on 11 March, 2014.

Xartemis Xr is available in tablet, extended release;oral dosage forms.

Xartemis Xr can be used as management of acute pain in patients requiring opioid analgesia, method of treating patients with gastric retentive dosage form.

The generics of Xartemis Xr are possible to be released after 16 May, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7976870 MALLINCKRODT INC Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
Jun, 2027

(4 years from now)

US8668929 MALLINCKRODT INC Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Mar, 2029

(6 years from now)

US8394408 MALLINCKRODT INC Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Mar, 2029

(6 years from now)

US8372432 MALLINCKRODT INC Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Mar, 2029

(6 years from now)

US8377453 MALLINCKRODT INC Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Nov, 2029

(6 years from now)

US8597681 MALLINCKRODT INC Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
Dec, 2030

(7 years from now)

US8980319 MALLINCKRODT INC Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
Dec, 2030

(7 years from now)

US8658631 MALLINCKRODT INC Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
May, 2032

(9 years from now)

US8741885 MALLINCKRODT INC Gastric retentive extended release pharmaceutical compositions
May, 2032

(9 years from now)

US9468636 MALLINCKRODT INC Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
May, 2032

(9 years from now)

US8992975 MALLINCKRODT INC Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
May, 2032

(9 years from now)

US9050335 MALLINCKRODT INC Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
May, 2032

(9 years from now)

Drugs and Companies using ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 March, 2014

Treatment: Method of treating patients with gastric retentive dosage form; Management of acute pain in patients requiring opioid analgesia

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic